Cybin seeks to build an international footprint via scaling up activities in Europe with its Ireland subsidiary, including the transfer of its IP assets.
Cybin seeks to build an international footprint via scaling up activities in Europe with its Ireland subsidiary, including the transfer of its IP assets.
Novamind's clinics have been selected as a research site by atai-partner, Bionomics Limited for a Phase IIb clinical trial.
MindMed's new partnership with Datavant will enhance its data-collection/data-reporting as MindMed moves through its clinical trials.
Analysts Jason McCarthy and Michael Okunewitch of Maxim Group have initiated coverage of Mind Cure Health.
MindMed officially announces its inclusion in the FTSE Russell 3000.
Cybin Inc releases its full-year financial results for the fiscal year ended March 31, 2021 and provides business highlights.
Psyched Wellness announces its latest pre-clinical study on AME-1.
In pre-clinical testing, multiple proprietary molecules "showed consistent positive results when compared to the parent molecule".
Compass Pathways completes the world's largest psilocybin-based clinical trial as the 216th patient in its trial completed their treatment.
Field Trip reports Q4 and full-year results for fiscal 2021. Cash position of CAD$111m. Clinic revenues increased by 63% q-o-q to CAD$526,435.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now